Literature DB >> 8885146

Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery.

L Knudsen1, J M Hasenkam, H H Kure, P Hughes, L Bellaiche, P Ahlburg, C Djurhuus.   

Abstract

UNLABELLED: Despite high plasma levels of heparin during cardiopulmonary bypass surgery, activation of the coagulation system has been reported. We hypothesize that the coagulation system activity most appropriately could be assessed by molecular markers of thrombin generation. The aim of the present study was to describe the changes in thrombin generation during CPB, using prothrombin fragment F1 + 2 (F1.2) as an indicator and evaluate different blood sampling regimens for interpretation of the F1.2 measurements. Twenty patients, operated under extracorporeal circulation with coronary artery bypass grafting (CABG), comprised the study material. The heparin levels were maintained above 2.5 IU/ml throughout the bypass procedure and the functional AT-III level was kept above 0.5 U/ml. Despite of this anticipated inactivation of the coagulation system, the concentrations of F1.2 and FpA increased throughout CPB, particularly after release of the aortic crossclamp. F1.2 and FpA correlated significantly (R = 0.69). No statistically significant correlation was found between F1.2 formation rate and age, bodyweight, baseline ACT, ACT after 200 IU heparin/kg, average heparin concentration during CPB or average AT-III level during CPB.
CONCLUSIONS: Thrombin formation seems to be a continuous process during CPB despite adequate heparinization. The pattern of thrombin generation can be assessed most appropriately in terms of F1.2 generation rate. Extraordinary high levels of F1.2 were seen after release of the aortic crossclamp, indicating that the periods before and after aortic crossclamping should be evaluated separately.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885146     DOI: 10.1016/0049-3848(96)00160-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

Review 1.  Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass.

Authors:  Maryam Yavari; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2008-01-23       Impact factor: 2.300

2.  Impact of a phosphorylcholine-coated cardiac bypass circuit on blood loss and platelet function: a prospective, randomized study.

Authors:  Sandrine Marguerite; François Levy; Astrid Quessard; Jean-Pierre Dupeyron; Cécile Gros; Annick Steib
Journal:  J Extra Corpor Technol       Date:  2012-03

Review 3.  Coagulation disorders of cardiopulmonary bypass: a review.

Authors:  Domenico Paparella; Stephanie J Brister; Michael R Buchanan
Journal:  Intensive Care Med       Date:  2004-07-24       Impact factor: 17.440

4.  Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass.

Authors:  Ruwan Gunaratne; Shekhar Kumar; James W Frederiksen; Steven Stayrook; Jens L Lohrmann; Kay Perry; Kristin M Bompiani; Charlene V Chabata; Nabil K Thalji; Michelle D Ho; Gowthami Arepally; Rodney M Camire; Sriram Krishnaswamy; Bruce A Sullenger
Journal:  Nat Biotechnol       Date:  2018-06-04       Impact factor: 54.908

5.  Children undergoing cardiac surgery for complex cardiac defects show imbalance between pro- and anti-thrombotic activity.

Authors:  Ruth Heying; Wim van Oeveren; Stefanie Wilhelm; Katharina Schumacher; Ralph G Grabitz; Bruno J Messmer; Marie-Christine Seghaye
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

6.  The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis.

Authors:  Meredith A Achey; Uttara P Nag; Victoria L Robinson; Christopher R Reed; Gowthami M Arepally; Jerrold H Levy; Elisabeth T Tracy
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.